Lucid Diagnostics Stock (NASDAQ:LUCD)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$1.06

52W Range

$0.95 - $1.70

50D Avg

$1.29

200D Avg

$1.16

Market Cap

$106.40M

Avg Vol (3M)

$779.25K

Beta

1.25

Div Yield

LUCD Company Profile

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Oct 14, 2021

Website

LUCD Performance

LUCD Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$4.71B	$4.35M	$2.43M
Operating Income	$-49.64B	$-46.05M	$-48.48M
Net Income	$-70.57B	$-45.53M	$-52.67M
EBITDA	$-49.64B	$-44.34M	$-49.75M
Basic EPS	$-0.69	$-1.05	$-1.26
Diluted EPS	$-0.69	$-1.05	$-1.26

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Mar 26, 26 | 8:30 AM

Q3 25Nov 12, 25 | 8:30 AM

Q2 25Aug 13, 25 | 8:30 AM

Peer Comparison

Ticker	Company
IRD	Opus Genetics, Inc.
AVR	Anteris Technologies Global Corp.
RPID	Rapid Micro Biosystems, Inc.
APYX	Apyx Medical Corporation
SEER	Seer, Inc.
OWLT	Owlet, Inc.
STSS	Sharps Technology, Inc.
RCEL	AVITA Medical, Inc.
IXHL	Incannex Healthcare Limited
SCLX	Scilex Holding Company